NCT02294279View on ClinicalTrials.gov

The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms

PHASE4CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Asthma
Interventions
DRUG

Qvar (100 mcg)

2 puffs twice daily; 400 mcg daily over 4 weeks treatment period

Trial Locations (1)

CB24 3BA

Research in Real Life Ltd, Oakington

Sponsors

Collaborators (1)

Aerocrine AB
All Listed Sponsors
collaborator

Aerocrine AB

INDUSTRY

lead

Research in Real-Life Ltd

NETWORK

NCT02294279 - The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms | Biotech Hunter | Biotech Hunter